Our prognostic results are parallel to this finding: LOXL4 positivity was associated with improved 2 year disease specific (78.3% vs. 59.6%) and overall (91.3% vs. 72.2%) survival independent of tumor differentiation, but this trend only reached statistical significance for 2 year overall survival. Here, LOXL4 is linked to neoplasm.